Inclusion Criteria:

- Male or female, age ranging from 18 yrs to 70 yrs, with histologically or
cytologically confirmed malignant disease

- naive to chemotherapy or nonnaive with an interval of at least 14 days to the last
one

- Karnofsky index more than 70% and anticipated survival time more than 90 days

- Scheduled to receive any of the following cytotoxic agents based combination
chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2) on study Day 1 and the
chemotherapy should be accomplished on study Day 1

- No emetic episodes and antiemetic medication during the 24 hours preceding
chemotherapy administration

- Adequate organ functions(No impairment to renal, hepatic, cardiac or bone marrow
function )

- Use of reliable contraceptive measures (for females of childbearing potential) and
negative pregnancy test at baseline visit

- Provision of written informed consent

Exclusion Criteria:

- Inability to understand or cooperate with study procedures

- Receipt of investigational drugs 30 days before study entry

- Scheduled to receive any drug with antiemetic efficacy from 24 hrs before to 5 days
after treatment

- Contraindications to 5-HT3 receptor antagonists

- Woman Patient with Pregnancy or lactation

- Diagnosed with hypertension or severe infectious diseases

- Obstructive symptom of gastrointestinal tract

- Symptomatic brain metastasis or mental dysfunction

- Baseline QTc > 500 ms